Track record · closed signal

Boston Scientific Corporation (BSX) — closed signal from July 9, 2025

Partial Published before the outcome was known, scored automatically when the window closed on October 7, 2025.

Predicted vs. what happened

BSX price · publication thesis → realized outcomesplit-adjusted
$102.41 Published $118.80 Target $95.90 Window close $109.50 Peak
$97.00 – $99.00Entry zone — fair-value band
$102.41Published — price the day we called it
$118.80Target — the price the thesis aimed for
$109.50Peak — highest point inside the window, not a realized return
$95.90Window close — end-of-window price, context only

What happened

Partial

Reached 43% of the predicted growth at its peak, without hitting the target.

Peak price
$109.50
peak on September 9, 2025 — not a realized return
Peak gain
+6.9%
peak, from the publication price
Window close
$95.90
end-of-window price, context only
Days to target
—
Window
July 9, 2025 – October 7, 2025

The thesis — published July 9, 2025

Predicted growth
+16%
over the measurement window
Target price
$118.80
the price the thesis aimed for
Entry zone
$97.00 – $99.00
the fair-value band we waited for
Price at publication
$102.41
published July 9, 2025
Confidence
66%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Recent selling pushed a key momentum gauge to an unusually low level, yet the firm is still growing sales at double digits. Two important FDA rulings on new heart treatments are due this quarter, and heavier-than-normal bullish option trades on July 7 show that big investors are positioning for good news. If the selling pressure fades, the price could snap back toward 118 dollars.

Primary drivers

  • A very low momentum reading hints that most sellers are already out.
  • Upcoming FDA rulings could open its devices to more patients.
  • Unusually heavy option buying shows large investors expect upside.
  • Sales are still rising more than 10 percent versus last year.

How it played out

BSX: target was not reached

Lyra published BSX at $102.41 on July 9, 2025, with 16% expected growth and a target of $118.80. The thesis pointed to a very low momentum reading, possible FDA rulings for heart treatments, unusually heavy option buying on July 7, and sales rising more than 10% versus last year.

Inside the window, BSX rose, but only part of the thesis played out. The stock peaked at $109.50 on September 9, a 6.9% gain. It never reached $118.80. By October 7, it ended at $95.90. The call had some early upside, but the target missed.

What happened during the window

On July 23, 2025, Boston Scientific reported second-quarter results. Investors Business Daily said sales rose 23% year over year to $5.06 billion, adjusted earnings were $0.75 per share, and the company raised its 2025 outlook.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All BSX signals